21948233 |
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors
Lovly, CM,
Grütter, C,
Heynck, S,
Sos, ML,
Thomas, RK,
Peifer, M,
Balke-Want, H,
Heuckmann, JM,
Rauh, D,
Koker, M,
Weiss, J,
Pao, W,
Hölzel, M
|
Clin. Cancer Res. |
2011 |
18923525 |
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Zozulya, S,
George, RE,
Gilliland, DG,
Morris, SW,
Luther, W,
London, WB,
Hanna, M,
Meyerson, M,
McGrady, P,
Sanda, T,
Gregor, VE,
Look, AT,
Zhang, J,
Fröhling, S,
Ahn, Y,
Diller, L,
Webb, TR,
Zhou, W,
Greulich, H,
Gray, NS,
Xue, L
|
Nature |
2008 |
27009859 |
TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors
Gokhale, V,
Groysman, MJ,
Pongtornpipat, P,
Wang, M,
Tapia, EO,
Rajan, SS,
Amin, AD,
Schatz, JH,
Li, L
|
Oncotarget |
2016 |
21791641 |
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
Zheng, W,
Lindeman, N,
Capelletti, M,
Gray, NS,
Wong, KK,
Christensen, JG,
Ercan, D,
Jänne, PA,
Rodig, SJ,
Shimamura, T,
Nikiforow, S,
Weremowicz, S,
Sasaki, T,
Okuda, K,
Wilner, K,
Eck, MJ,
Butaney, M,
Stumpfova, M,
Yanagita, M,
Heon, S,
Ogino, A,
Xiao, Y,
Marcoux, JP,
Koivunen, J,
Lathan, C,
Du, J
|
Cancer Res. |
2011 |